Better Method Found to Determine Bone Marrow Involvement in DLBCL

Researchers have discovered a better way of determining whether patients with diffuse large B-cell lymphoma (DLBCL) have bone marrow involvement – a development that should lead to better decisions about frontline treatment.

The study

Reporting in the August issue of the Journal of Nuclear Medicine , researchers led by Loius Berthet, M.D., carried out a retrospective study of 133 patients diagnosed with DLBCL. All patients underwent both a bone marrow biopsy and a whole-body 18F-FDG PET/CT scan.

Berthet said:

In our study, we showed that in diffuse large B-cell lymphoma, 18F-FDG PET/CT has better diagnostic performance than bone marrow biopsy to detect bone marrow involvement and provides a better prognostic stratification. While bone marrow biopsy is considered the gold standard to evaluate bone marrow involvement by high-grade lymphomas, 18F-FDG PET/CT is in fact the best method to evaluate extension of the disease, as well as avoid invasive procedures.

Compared to bone marrow biopsy, 18FDG PET/CT was:

  • More sensitive (94 percent vs. 24 percent)
  • Showed a higher negative predictive value (98 percent vs. 80 percent)
  • More accurate (98 percent vs. 81 percent)

The results

A total of 26 patients were found to have positive 18F-FDG PET/CT results but negative biopsy results. Eleven of them were restaged as stage IV by PET/CT. This effectively changed their treatment plans.

Added Berthet:

Our findings add to the literature to prove the significance of 18F-FDG PET/CT in cancer evaluation and to democratize this imaging method. Molecular imaging is the best method to adapt targeted therapies to each patient. The emergence of PET/MRI and novel radiotracers predicts an exciting new future for our field.

Source: snm.org

More Articles

More Articles

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

In a large trial of older, newly diagnosed patients with chronic lymphocytic leukemia (CLL),...

Today’s typical treatments have been unable to cure numerous types of lymphoma, but emerging immunotherapies could provide the key to...

Biotech firm Gilead Sciences Inc. has announced that the first patient has been dosed in a Phase III trial evaluating the safety and efficacy of...

Last week at the 54th American Society of Hematology Annual Meeting and Exposition in Atlanta, researchers out of MD Anderson Cancer Center in...

The results of a pair of long-term survival studies indicate the therapeutic value of BEXXAR (...

A new lab test that can improve survival rates among patients with chronic lymphocytic leukemia (...

Aggressive Non-Hodgkin’s Lymphomas (NHLs) are fast growing cancers (as opposed to indolent cancers). They involve...

A B cell is a type of lymphocyte that produces antibodies to fight infections. These are the most prevalent lymphocytes in the bloodstream and are...

Sitemap